- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00730184
Does Potassium Bicarbonate Improve the Effect of Dietary Protein on Bone and Muscle?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The balance between the amount of protein in the diet (anabolic component) and the net acid load of the diet (catabolic component) in part determines whether the diet as a whole has a net anabolic or catabolic effect on bone and muscle. This study will investigate whether the addition of an alkaline salt of potassium, potassium bicarbonate, will allow dietary protein to have a more favorable net impact on intermediary indices of bone and muscle conservation than is observed with protein in the usual acidic environment.
Men and postmenopausal women, age 50 and older, will be enrolled in this 42-day study in order to have 20 completers. Subjects may continue in the study for up to an additional two weeks should this be necessary for reasons related to intercurrent illness (unrelated to the research) or scheduling circumstances. Over the first 15 days, subjects will be placed on gradually increasing doses, up to a maximum of 90 mmol/d of potassium bicarbonate or placebo. They will remain on this dose for the rest of the study. Subjects will then have two 10-day metabolic diet cycles each, in random order, as follows:
Group 1 - low protein diet (0.5 g/kg/d) then high protein diet (1.5 g/kg/d) Group 2 - high protein diet (1.5 g/kg/d) then low protein diet (0.5 g/kg/d)
There will be a 5-day period between the two metabolic diets in which subjects consume their usual diets but continue to take the study pills.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- This study will be conducted in subjects with body mass index < 38 kg/m2.
- Women must be at least 6 months since last menses.
- Subjects must be willing to maintain their usual exercise level and agree not to attempt to gain or lose weight or change their diets substantially during the study.
- Subjects will not be allowed to take their own calcium or vitamin D supplements from one week before their screening visit through the end of the study.
- They must also agree not to ingest bicarbonate- or potassium-rich products such as selected antacids and salt substitutes during the study.
- They must also agree not to consume alcohol during the study.
Exclusion Criteria:
Medications
- Oral glucocorticoid use for > 10 days in the last 3 months
- Estrogen, raloxifene, or calcitonin use in the last 6 months, bisphosphonate or teriparatide use in the last 2 years
- Current use of diuretics
- Regular use of NSAIDS (> 3 times per wk) or anabolic drugs (steroids or other). Note that subjects may use acetominophen for joint or other discomforts during the study.
Conditions/Diseases
- Renal disease including kidney stones in the past 5 years or creatinine clearance < 50 ml/min/1.73 X m2 of body surface area
- Cirrhosis
- GERD requiring treatment with alkali-containing antacids (use of Lowsium okay)
- Hyperparathyroidism
- Untreated thyroid disease
- Significant immune disorder such as rheumatoid arthritis, SLE
- Current unstable heart disease
- Active malignancy or cancer therapy in the last year
- 24-hr urine calcium > 300 mg/d after 1 wk off of calcium supplements
- Subjects with arrythmias (surgically treated arrythmias acceptable), or myocardial infarction in last 12 months
- Total hip T score of < -3.0
- Abnormal serum calcium; alkaline phosphatase >10% above the upper end of the reference range
- Adrenal insufficiency, primary aldosteronism, Bartter's syndrome
- Diabetes mellitus (fasting blood sugar > 130)
- Alcohol use exceeding 2 drinks/day
- Peptic ulcers or esophageal stricture
- Screening serum 25(OH)D levels below 16 ng/ml
- Vegetarians
- Other abnormalities in screening labs, at discretion of the study physician (principal investigator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
Participants receive potassium bicarbonate in dosage of 90 mmol/d.
This compound has no other name.
|
90 mmol/d given as 4 tablets after each meal, with a full glass of water
|
PLACEBO_COMPARATOR: 2
Participants receive placebo as microcrystalline cellulose.
This compound has no other name.
|
Given as 4 tablets after each meal, with a full glass of water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the impact of administration of an alkalinizing salt on urinary nitrogen excretion in older men and women.
Time Frame: before and after low and high protein diet cycles
|
before and after low and high protein diet cycles
|
To determine the impact of administration of an alkalinizing salt on urinary calcium excretion in the same population.
Time Frame: before and after low and high protein diet cycle
|
before and after low and high protein diet cycle
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine whether the administration of an alkalinizing salt of potassium alters the effect of protein on biochemical markers of bone turnover in the same population.
Time Frame: before and after low and high protein diet cycles
|
before and after low and high protein diet cycles
|
To determine whether the administration of an alkalinizing salt of potassium alters the effect of protein on calcium absorption in the same population.
Time Frame: before and after low and high protein diet cycles
|
before and after low and high protein diet cycles
|
To determine whether the administration of an alkalinizing salt of potassium alters the effect of protein on serum IGF-1 in the same population.
Time Frame: before and after low and high protein diet cycles
|
before and after low and high protein diet cycles
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Lisa Ceglia, MD, Tufts University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2510
- 7937
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on potassium bicarbonate
-
DLR German Aerospace CenterUniversity of Aarhus; University of Trieste; European Space AgencyCompletedSprains and Strains | Body Weight Changes | Muscular Atrophy | Bone Diseases, Metabolic | Cardiovascular Abnormalities | Acid-Base Imbalance | Protein MetabolismGermany
-
Tufts UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedFall Injury | Muscle Loss | Fractures | Osteoporosis, Age RelatedUnited States
-
Tufts UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedSarcopenia | OsteoporosisUnited States
-
Baptist Health South FloridaTerminatedHypokalemiaUnited States
-
University of Texas Southwestern Medical CenterNot yet recruitingKidney StoneUnited States
-
DLR German Aerospace CenterMedical University of Graz; Radboud University Medical Center; Charite University... and other collaboratorsCompleted
-
NorgineCompletedConstipationUnited Kingdom, Italy, Czech Republic, France, Germany, Poland, Sweden
-
Advicenne PharmaTerminatedDistal Renal Tubular AcidosisUnited States, Canada
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
European Georges Pompidou HospitalInstitut National de la Santé Et de la Recherche Médicale, France; Sponsor...CompletedGlomerulonephritis | Cystinuria | Renal Lithiasis | Interstitial NephritisFrance